SCHEMBL5536668

SCHEMBL5536668

COc1ccc(CN2CC[N]C2=O)cc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.55
CMA1 P23946 1/20 0.51
GSK3A P49840 2/20 0.49
GSK3B P49841 2/20 0.49
SIGMAR1 Q99720 1/20 0.47
GRM2 Q14416 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.46
POLB P06746 1/20 0.46
ALDH1A1 P00352 3/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C19 P33261 1/20 0.45
MAPT P10636 2/20 0.44
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
MMP1 P03956 1/20 0.44
MMP13 P45452 1/20 0.44
KDM4E B2RXH2 1/20 0.44
ALOX15 P16050 1/20 0.44
HDAC1 Q13547 1/20 0.43
PTGIR P43119 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9705989 0.91 GAA (0.52) GAACMA1GSK3AGSK3BSIGMAR1
SCHEMBL5539616 0.85 ACACB (0.53) GAAGRM2SMN1; SMN2POLBALDH1A1
SCHEMBL5537205 0.84 ROCK2 (0.42) GAACMA1MEN1KMT2A
SCHEMBL5536814 0.84 P2RX3 (0.46) GRM2POLBMAPTMEN1KMT2A
SCHEMBL5540360 0.82 TSHR (0.54) GAAALDH1A1MEN1KMT2A
SCHEMBL5545709 0.82 CMA1 (0.56) GAACMA1SIGMAR1ALDH1A1MAPT
SCHEMBL9704359 0.81 KMT2A (0.51) SIGMAR1SMN1; SMN2ALDH1A1MAPTMEN1
SCHEMBL5546843 0.80 RAB9A (0.54) GAAALDH1A1MEN1KMT2A
SCHEMBL5543146 0.80 ERCC1 (0.46) SIGMAR1GRM2SMN1; SMN2ALDH1A1KDM4E
SCHEMBL5541487 0.79 NPC1 (0.56) GAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed
EP-0470543-A1 Heterocyclic imidazoles, remedies containing them and processes for their preparation Dr. Karl Thomae GmbH (DE) 1992-02-12 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 GAA 4165/4885CMA1 4476/4885GSK3A 3321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.